TangGene Scientific Co-Founders Publish Invited Review on CD8⁺ Tregs in Annual Review of Immunology
December 6, 2025
TangGene is pleased to announce that its two scientific co-founders, Prof. Harvey Cantor (Harvard Medical School / Dana-Farber Cancer Institute) and Prof. Xiaolei Tang, have authored an invited review article published in Annual Review of Immunology, a leading review journal in the field of immunology.
The article provides a comprehensive overview of recent advances in CD8⁺ regulatory T cells (CD8⁺ Tregs) and highlights a nanoparticle-enabled, precision in vivo therapeutic approach—adopted by TangGene’s platform—to selectively activate tissue-specific, HLA-E–restricted CD8⁺ Tregs.
This publication reinforces TangGene’s strong scientific foundation and reflects growing recognition of CD8⁺ Tregs as a precise and promising pathway for treating multiple sclerosis (MS) and other autoimmune diseases.
Reference:
